INTERCURE LTD (INCR)

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

The funding may increase to NIS 107M to support the expansion of the facility in collaboration with the "Tkumah" administration, post-war. The funding includes...

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA1of NIS 21 million (Approximately 17% of revenues).Both...

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million

InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million

InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint

InterCure provides update regarding its Nir Oz facility (NASDAQ:INCR)

InterCure (INCR) updates on the status of its facility in Kibbutz Nir Oz in Southern Israel, with limited access granted and restoration efforts underway.

InterCure Provides an Update Regarding Nir Oz Facility

NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) (

InterCure to buy Isreal-based Leon cannabis pharmacy chain (NASDAQ:INCR)

InterCure, a financial company, has agreed to purchase Leon Pharm, an Israeli-based pharmacy chain specializing in medical cannabis dispensing.

InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain

NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) (

Court rules in InterCure's favor in Cannolam arbitration process (NASDAQ:INCR)

InterCure wins arbitration process in Cannolam case, gaining full ownership of subsidiary and exclusive rights to the Cookies brand in Israel. Read more.

InterCure Wins Cannolam Arbitration Proceeding

NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) (

InterCure Provides an Update Regarding the Security Situation in Israel

NEW YORK, and HERZLIYA, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) (

Monday Sector Laggards: Biotechnology, Drugs

InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY

Achieved record revenues of NIS 209 million ($75 million)1 for the first half of 2023 Annualized revenue run rate of NIS 417...

InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE

NEW YORK and TORONTO and HERZLIYA, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba...

InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

NEW YORK and TORONTO and HERZLIYA, Israel, June 09, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba...

InterCure to Participate in the Cowen 3rd Annual European Cannabis Conference

Mr. Rabinovitch is one of the global cannabis senior executives to participate ...

InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY

Achieved record revenues of $40 million for the first quarter Annualized revenue run rate of $159 million Adjusted EBITDA(1) of $6 Million ...

InterCure to Be Featured with Mike Tyson in an Exclusive Interview on Fox Business

The Company will be featured on the Claman Countdown show on Monday to discuss its strong 2022 results and recent partnership with Mike Tyson...